Impact of iron chelation with deferasirox on telomere length and oxidative stress in hemodialysis patients: A randomized study
Deferasirox
DOI:
10.1016/j.nefro.2024.06.006
Publication Date:
2024-06-14T20:37:54Z
AUTHORS (6)
ABSTRACT
Background: Recent studies have demonstrated the effectiveness, safety, and tolerability of deferasirox in patients peritoneal dialysis, however, its effect has not been studied undergoing hemodialysis. Objective: To investigate impact iron chelation on telomere length, oxidative stress, ferritin levels Methods: This is an open-label study, with a control group hemodialysis, who will receive treatment 15mg/kg/day for 6 months chelation. Telomere length was measured using real-time PCR. Serum Ferritin oxidation markers were evaluated. evaluate pharmacokinetics safety deferasirox, plasma concentrations analyzed by HPLC. Results: 54 included to 50 patients. Significant differences observed serum (p<0.0001), TBARS (Thiobarbituric Acid Reactive Substances) (p<0.01). had significant increase after (p<0.001). The concentration at zero time 48 hours maintained within range 2.67 23.78 mmol/L. Conclusions: Our results demonstrate that hemodialysis significantly reduces TBARS, resulting length. Deferasirox proves be beneficial overload
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (49)
CITATIONS (1)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....